Articles tagged with Prostate Cancer
A new study found that the gut microbiota plays a significant role in prostate inflammation in aging men, particularly those with metabolic syndrome. The researchers discovered a strong relationship between IL-6 and IL-18 expression and lipid parameters in the prostate tissue of men with BPH + MetS.
Researchers found that Black men are more likely to have prostate cancer than white men, regardless of PSA level. This highlights the importance of earlier and more frequent screening for Black men to reduce health disparities.
Men who are overweight or obese at age 18 have a higher risk of developing 17 different cancers later in life. Higher BMI is also associated with an increased risk of mortality after cancer diagnosis for certain types of cancer.
Researchers found that a specific gene, MDA-9, initiates a cellular chain reaction sparking prostate cancer metastasis. The study's findings hold significant implications for treating prostate cancer and other forms of disease.
A phase 1 trial of the radiopharmaceutical 225AC-J591 demonstrated promising antitumor activity against advanced metastatic prostate cancer, reducing PSA levels by at least half for 47% of patients. The treatment was well-tolerated, with only temporary low blood cell count side effects.
A new study finds that systemic therapies for advanced prostate cancer are equally effective for Black men as they are for white men, regardless of socioeconomic status. The research suggests that disparities in healthcare can be eliminated with equal access to treatment.
Cedars-Sinai Cancer investigators have identified two promising new treatment options for men with recurrent prostate cancer, improving metastasis-free survival and quality of life. The combination therapy reduced the risk of metastasis or death by 58%, while enzalutamide alone was effective in preventing cancer spread or death.
A simple MRI scan and a new metric for prostatic urethra length may help identify men at risk of chronic urinary side effects after radiation therapy. The study found that longer prostatic urethras are associated with a higher likelihood of these symptoms, which can impact quality of life.
A recent study of nearly 13,000 veterans with nonmetastatic castration-resistant prostate cancer found that Black and Hispanic men have improved outcomes when treated in equal-access settings. The research highlights the need for targeted care to address racial disparities in healthcare outcomes.
Scientists at Mays Cancer Center found that altering androgen receptor multivalent interactions may lead to new treatments for prostate cancer. The study suggests that precise levels of these interactions are crucial for proper hormone-induced gene expression.
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
A new study found that precision medicine navigators can significantly increase genomic testing rates for Black patients with prostate cancer. Genomic testing is used to gauge the likelihood of cancer metastasis and has been shown to be more accurate than traditional tests in predicting treatment outcomes.
A phase III trial suggests that fewer and higher doses of radiation therapy delivered over five sessions are as effective as lower doses delivered over several weeks for patients with locally advanced disease. The treatment achieved a 96% five-year disease control rate, comparable to 95% for conventional radiation.
Researchers found persistent inflammation in intestines of patients 20 years post-radiotherapy, even with targeted treatments. This could lead to chronic symptoms like tenesmus and frequent diarrhea.
The American Society for Radiation Oncology announced the winners of its new combination therapy challenge, which aims to improve prostate cancer treatments using relugolix in combination with radiation therapy. The three winning research proposals will receive funding over four to five years.
A scoping review identified four key themes: everyday language, thorough information, adequate discussion time, and a trusting relationship. The study also highlighted the impact of racism on Black men's medical interactions. Researchers suggest strategies to support men's communication preferences.
Researchers have identified 11 genes associated with aggressive prostate cancer, which could lead to more effective treatments and earlier detection. The findings come from a large-scale study of over 17,500 patients and may help personalize care for individuals with the disease.
A study comparing PI-RADS 2.0 and 2.1 found no significant differences in upgrade (29% vs. 22%) or downgrade (19% vs. 21%) rates from targeted biopsy to radical prostatectomy, suggesting no improvement in prostate cancer grade assessment with the latest PI-RADS update.
Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.
Researchers identified how prostate cancer cells achieve cell growth free from usual growth cues and regulators. A protein called PLEKHS1 was found to be a major driver of PI3K activation and cancer growth progression in mouse models.
Research published in BMJ Oncology reveals a global increase of 79% in new cancer cases among those under 50 between 1990 and 2019. Breast cancer accounted for the highest number of early onset cases, while cancers of the windpipe and prostate rose the fastest.
The Society of Nuclear Medicine and Molecular Imaging has issued a new consensus statement to standardize the selection and management of patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with Lu-177 PSMA radionuclide therapy. The statement recommends performing PSMA PET within three months of treatment or sin...
A free online tool can help prostate cancer patients save thousands of dollars in out-of-pocket drug costs by comparing Medicare Part D prescription plans. The Medicare Part D Plan Finder identifies significant savings for patients taking abiraterone or enzalutamide, two common prescription drugs for advanced prostate cancer.
Researchers evaluated biochemical recurrence as a surrogate endpoint for overall survival, but found no reliable correlation. Biochemical recurrences occur early in the disease course and may impact quality of life, but high-level data tracking this is lacking.
A new study found that MRI scans with prostate-specific antigen density can detect serious prostate cancers earlier, while reducing unnecessary biopsies. The REIMAGINE trial suggested that MRI could be a more reliable method of detecting potentially serious cancers early, with minimal overdiagnosis.
Researchers have found that a prostate cancer drug called proxalutamide can block SARS-CoV-2 viral entry and reduce inflammation. The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.
A team of researchers has identified four metabolism-related biomarkers associated with an increased risk of metastatic prostate cancer in men of West African heritage. These findings could lead to improved testing and treatments for patients.
A new study has discovered that metformin, a common diabetes medication, can significantly slow the progression of STAT3-positive prostate cancer. The research team identified the key factors regulating tumour cell growth and found that permanent activation of STAT3 prevents prostate cancer development and metastasis.
Researchers at Sylvester Comprehensive Cancer Center are working on a new urine test to detect prostate cancer, reducing the need for invasive biopsies. They will use exosomes, small extracellular vesicles, as a promising new biomarker and collaborate with Exosome Diagnostics.
A study found that PSMA PET/CT can accurately diagnose advanced prostate cancer in elderly patients without the need for a biopsy. The procedure reduced the number of biopsies and associated complications, while providing clinical suspicion-based staging data.
Researchers have found a promising new mechanism to target aggressive forms of prostate cancer, where the LSD1 protein is involved. By inhibiting LSD1, the tumor suppressor gene p53 can be reactivated, leading to suppression of tumor growth.
A Harvard T.H. Chan School of Public Health study found that chronic exposure to fine particulate air pollutants (PM2.5) and nitrogen dioxide (NO2) increases the risk of colorectal and prostate cancers in older adults. NO2 exposure was also associated with an increased risk of breast cancer, while PM2.5 exposure had mixed results.
Researchers found that hospitals treating a higher volume of patients with aggressive prostate cancer have better outcomes, indicating a possible association between expertise and resource availability. Further investigation is needed to understand the specific causes behind this relationship.
A meta-analysis of multiple studies found no association between depression and anxiety and most types of cancer. However, the study found a link between depression and anxiety with a 6% higher risk of developing lung cancer and smoking-related cancers.
A study by Harvard T.H. Chan School of Public Health found that chronic exposure to fine particulate air pollutants (PM2.5) and nitrogen dioxide (NO2) may increase non-lung cancer risk in older adults, with significant associations with colorectal and prostate cancers.
A study published in JAMA Network Open found that providing equal access to healthcare reduces disparities in treatment outcomes between Black and white patients with advanced prostate cancer. The research suggests that addressing racial disparities in healthcare may improve survival rates for this patient group.
PSMA PET imaging provides prognostic information on cancer recurrence risk before treatment, improving personalized treatments and guiding surgical plans. The tool outperforms current standard tests in predicting biochemical recurrence, a critical factor in determining cancer-specific mortality.
A study of 29 clinical trials found that MRg-A-SBRT significantly reduces urinary and bowel side effects in prostate cancer patients, with a 44% reduction in urinary and 60% reduction in bowel side effects. This technique uses imaging technology to accurately aim radiation beams at the prostate while avoiding nearby tissue.
A new multiplex assay has been developed to assess activated p300/CBP in circulating prostate tumor cells, revealing correlations with clinical outcomes and potential therapeutic targets for castration-resistant prostate cancer. The study found that patients with upregulated p300/CBP activity had shorter response times to ARSI therapy.
Researchers at the University of South Australia have discovered three new biomarkers for prostate cancer that can accurately visualize and grade the disease. The breakthrough technology will enable clinicians to determine which patients require immediate treatment, potentially saving thousands of lives annually.
A new study published in JAMA Network Open found that Black Americans are more likely to trust videos about prostate cancer presented by a Black doctor. The study, led by researchers at NYU Grossman School of Medicine, involved over 2,900 participants and showed that racial diversity among healthcare providers is crucial for improving ...
Sylvester Comprehensive Cancer Center researchers developed a first-of-its-kind orally administered drug Platin-L to disrupt prostate cancer cells' metabolism and deliver cisplatin directly into treatment-resistant cancer cells. The study showed that Platin-L is safe and effective in shrinking treatment-resistant cancers.
Researchers have developed a new therapy that disrupts prostate cancer cell metabolism and releases cisplatin, causing cells to die. In mouse models, the treatment shrunk tumors substantially, with no peripheral neuropathy or weight loss.
A new study reveals Indigenous men in Canada are more likely to be diagnosed with advanced prostate cancer and experience cancer spread, despite universal healthcare access. Researchers identify key infrastructure changes needed to improve screening and treatment outcomes.
A study found that 79 patients experienced high financial toxicity, with 89% reporting hardship, and highlighted patient characteristics and coping strategies. Patients made personal sacrifices to remain compliant with treatments, including reducing spending and borrowing money.
A new study published in NEJM Evidence validates a predictive AI biomarker for androgen deprivation therapy (ADT) benefit in prostate cancer. The study found that personalized use of short-term ADT could improve patient outcomes in men with predominantly intermediate-risk prostate cancer.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
A new AI model has been developed to help doctors determine the extent of cancer within the prostate gland, improving the effectiveness of focal therapy. The model was found to be more accurate than magnetic resonance imaging (MRI) in predicting tumor margins, reducing the chance of cancer recurrence.
A study found that monitoring early-response biomarkers enables personalized dosing in prostate cancer treatment, improving patient outcomes. The approach allowed patients to take
A new prostate cancer treatment combining enzalutamide and talazoparib has been approved by the FDA, offering improved patient outcomes. The treatment was found to decrease the risk of cancer progression by 55% in a phase 3 trial.
A randomized phase II study found that adding metformin to androgen deprivation therapy did not reduce the risk of metabolic syndrome or improve PSA response in patients with advanced prostate cancer. Metformin showed some antitumor effects through mTOR inhibition, but these were not significant.
The study found no improvement in freedom from progression rates for patients receiving combined EBRT and brachytherapy (COMBO) compared to those receiving brachytherapy alone (BT). Late adverse events were significantly increased in the COMBO arm, favoring BT as a standard of care for intermediate-risk prostate cancer patients.
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
A new study found significant reductions in breast, colorectal and prostate cancers as well as melanoma diagnoses in Alberta during the COVID-19 pandemic. Diagnoses dropped by 43% for melanoma, 36% for colorectal and prostate, and 33% for breast cancer during the 'state of emergency' phase.
Research in mice suggests that prostate cancer cells adapt to testosterone-deprivation therapy by producing cholesterol and generating their own testosterone. Treating aggressive tumors with inhibitors slows tumor growth. The study also points to a possible drug combination and sheds light on racial disparities in prostate cancer.
A research team has identified a previously unknown weak spot in prostate cancer cells that could lead to new therapeutic approaches for other types of cancer. The study found that inhibiting this process can reduce cancer growth without affecting normal cell growth.
A recent study found that American Indian and Alaska Native men are significantly less likely to receive prostate-specific antigen (PSA) testing and digital rectal exams from primary care providers compared to White men. This disparity results in poorer prostate cancer outcomes, particularly for men between 50-59 years old.
A large genome-wide association study identified novel PSA-associated variants and developed a polygenic score to correct for genetic variations in PSA levels. This approach improved biopsy referral decisions, reducing unnecessary procedures while detecting more aggressive tumors.
The SWOG Cancer Research Network will present 30 abstracts at the ASCO 2023 annual meeting, highlighting primary results from trials S1011, S1826, S1714, and S1929. Additionally, analysis from the S1609 DART trial will be shared publicly during the meeting.
A large-scale retrospective analysis by Sylvester Comprehensive Cancer Center researchers found that differences in care, rather than genetics, likely explain disparities in advanced prostate cancer between men of African and European ancestries. Men of African ancestry are less likely to receive comprehensive genetic profiling and tar...